

Reviewer 1, v.1

Comments to the Author

Comments:

No dose-response to ICG001 was performed. Likewise, in in vitro experiments a single ICG001 concentration was used. Reasons for choosing a single dose or concentration of ICG001 should be explained.

Line 54: I would suggest including a sentence mentioning that efficacy of pharmacotherapies, including ICS and LTRA, in preventing airway remodelling in patients with asthma is limited (Drug Discov Today. 2011 Dec;16(23-24):1084-91; Mini Rev Med Chem. 2008 Jun;8(7):647-56).

Line 68-71: I would suggest providing some information on TGF β receptor (J Allergy Clin Immunol. 2016 Oct;138(4):984-1010).

Line 82: please, revise this sentence.

Line 88: I would suggest deleting "therapeutic effect and".

Line 235-236: is there any evidence for that?

Line 238-239: were symptoms in various experimental groups quantified?

Line 348-350: likewise, this is too simplistic (Am J Respir Crit Care Med. 2015 Jul 15;192(2):164-71).

Line 358-359: this sentence is unclear and should be rephrased.

Line 435: I would suggest including a reference.

Line 451: replace "asthma" with "ovalbumin-sensitised mice after ovalbumin-challenge".

In the discussion, it should be emphasised that the further studies are required to clarify the role of these pathogenetic pathways in patients with asthma.